基于匈牙利全国数据库研究的第二代长效注射抗精神病药物的比较有效性:最新情况
Péter Takács1, Péter Kunovszki1, Valeria Timtschenko2
1Janssen Global Services LLC, Budapest, Hungary.
Schizophrenia bulletin open
|August 15, 2024
概括
在匈牙利的精神分裂症患者中,第二代抗精神病药物长效注射剂 (LAI) 与口服抗精神病药物 (OAP) 相比,治疗延续率显著更高,停药时间更长. 新的LAI,特别是每3个月一次的paliperidone,在较旧的治疗方法中表现出更高的坚持性.
科学领域:
- 药理学和精神病学 药理学和精神病学
- 在心理健康治疗中的现实世界证据.
背景情况:
- 之前的研究表明,与口服抗精神病药 (OAP) 相比,第二代抗精神病药长效注射剂 (SGA LAI) 的坚持更好.
- 更新的比较是必要的,以评估新的SGA LAIs与匈牙利的OAP相比.
研究的目的:
- 为了在匈牙利精神分裂症患者中比较新的SGA LAI和OAP之间的治疗延续率和停止时间.
- 评估不同SGA LAI配方和OAP的实际有效性.
主要方法:
- 从匈牙利国家医疗保险基金获得的非识别索赔数据的追溯分析.
- 包括2016年11月至2017年6月期间新开始接受SGA的精神分裂症患者.
- 主要结局:1年和1.5年因任何原因停药率和停药的中位时间.
主要成果:
- 长效注射药使用者 (26.4%) 的1年 (26.4%-78.6%) 和1.5年 (24.9%-76.4%) 的持续率高于口服抗精神病药使用者 (73.6%) (1年:12.7%-34.1%;1.5年:9.3%-29.5%).
- 与OAPs (52-152天) 相比,LAI (125-491天) 的中位时间到停止治疗是显著更长的.
- 帕利佩里每3个月 (PP3M) 和阿里皮普拉的LAI显示,与OAP相比,停药风险明显较低 (P < .01);PP3M也表现优于其他LAI (P < .05).
结论:
- 第二代抗精神病药物LAI在维护匈牙利精神分裂症患者的治疗坚持方面比OAP具有显著的优势.
- 较新的LAI配方,如每3个月一次的paliperidone,与OAP和可能较旧的LAI配方相比,似乎可以提供更好的长期治疗坚持.
相关概念视频
Antipsychotic Drugs: Typical and Atypical Agents
164
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
164
Psychosis: Goals of Pharmacotherapy
114
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
114
Antipsychotic Drugs: Therapeutic Uses and Side Effects
135
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
135
Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
Psychosis and Antipsychotic Drugs: Overview
208
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
208
Oral Hypoglycemic Agents: Glinides
149
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
149


